Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “EGFR-Mutant Lung Cancer”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Testing effectiveness (Phase 2)Study completedNCT02064491
What this trial is testing

Erlotinib Treatment Beyond Progression in EGFR Mutant NSCLC

Who this might be right for
Non-small Cell Lung Cancer
Finnish Lung Cancer Group 18
Not applicableActive Not RecruitingNCT03969823
What this trial is testing

Whole Genomic Landscape of Advanced EGFR-mutant NSCLC

Who this might be right for
Locally Advanced or Metastatic NSCLC
Seoul National University Hospital 148
Testing effectiveness (Phase 2)Study completedNCT02321540
What this trial is testing

A Phase I/II Study of Ibrutinib in Previously Treated Epidermal Growth Factor Receptor (EGFR) Mutant Non-Small Cell Lung Cancer

Who this might be right for
Lung Cancer
M.D. Anderson Cancer Center 13
Testing effectiveness (Phase 2)UnknownNCT06020989
What this trial is testing

Lazertinib and Chemotherapy Combination in EGFR-mutant NSCLC Patients Without ctDNA Clearance After lead-in Lazertinib Monotherapy

Who this might be right for
Non Small Cell Lung Cancer
Yonsei University 129
Early research (Phase 1)Study completedNCT02040064
What this trial is testing

Tolerability and Efficacy of Tremelimumab in Combination With Gefitinib in NSCLC Patients

Who this might be right for
Non Small Cell Lung Cancer
Gustave Roussy, Cancer Campus, Grand Paris 27
Large-scale testing (Phase 3)Study completedNCT01724801
What this trial is testing

Icotinib or Whole Brain Irradiation in EGFR-mutant Lung Cancer

Who this might be right for
Brain MetastasisNon Small Cell Lung Cancer
Guangdong Association of Clinical Trials 176
Testing effectiveness (Phase 2)Ended earlyNCT01526928
What this trial is testing

Study to Evaluate Safety, Pharmacokinetics, and Efficacy of Rociletinib (CO-1686) in Previously Treated Mutant Epidermal Growth Factor Receptor (EGFR) in Non-Small Cell Lung Cancer (NSCLC) Patients

Who this might be right for
Locally Advanced or Metastatic Non Small Cell Lung Cancer
Clovis Oncology, Inc. 612
Early research (Phase 1)Active Not RecruitingNCT03567642
What this trial is testing

The Combination of Osimertinib, Platinum and Etoposide for Patients With Metastatic EGFR Mutant Lung Cancers

Who this might be right for
Lung Cancer
Memorial Sloan Kettering Cancer Center 11
Large-scale testing (Phase 3)Ended earlyNCT02186301
What this trial is testing

TIGER-1: Safety and Efficacy Study of Rociletinib (CO-1686) or Erlotinib in Patients With EGFR-mutant/Metastatic NSCLC Who Have Not Had Any Previous EGFR Directed Therapy

Who this might be right for
Non-Small Cell Lung Cancer
Clovis Oncology, Inc. 100
Testing effectiveness (Phase 2)Study completedNCT01415011
What this trial is testing

Efficacy and Safety Study of Afatinib to Treat Lung Cancer Patients

Who this might be right for
Carcinoma, Non-Small-Cell Lung
University College, London 39
Not applicableUnknownNCT04778800
What this trial is testing

A Dose Exploration Study of Almonertinib for EGFRm NSCLC Patients With Brain/Leptomeningeal Metastasis (ARTISTRY)

Who this might be right for
NSCLCBrain MetastasesLeptomeningeal Metastasis
Henan Cancer Hospital 60
Testing effectiveness (Phase 2)Study completedNCT03455829
What this trial is testing

G1T38, a CDK 4/6 Inhibitor, in Combination With Osimertinib in EGFR-Mutant Non-Small Cell Lung Cancer

Who this might be right for
Carcinoma, Non-Small-Cell LungLung CancerNon-small Cell Lung Cancer
G1 Therapeutics, Inc. 30
Testing effectiveness (Phase 2)Looking for participantsNCT06106802
What this trial is testing

Lazertinib & Tepotinib for EGFR Mutant NSCLC in MET Overexpressed or Amplified Who Progressed After Lazertinib Treatment

Who this might be right for
Non-Small Cell Lung Cancer Metastatic
Sehhoon Park 47
Early research (Phase 1)Ended earlyNCT04862780
What this trial is testing

(SYMPHONY) Phase 1/2 Study Targeting EGFR Resistance Mechanisms in NSCLC

Who this might be right for
Lung NeoplasmsCarcinoma, Non-Small-Cell LungRespiratory Tract Neoplasms+21 more
Blueprint Medicines Corporation 177
Large-scale testing (Phase 3)UnknownNCT04500704
What this trial is testing

Almonertinib Plus Chemotherapy as First-line Treatment in Patients With EGFR Concomitant Non-EGFR Driver Gene Mutant, Locally Advanced or Metastatic NSCLC

Who this might be right for
Non Small Cell Lung Cancer
Cancer Institute and Hospital, Chinese Academy of Medical Sciences 166
Testing effectiveness (Phase 2)Ended earlyNCT03066206
What this trial is testing

Poziotinib in EGFR Exon 20 Mutant Advanced NSCLC

Who this might be right for
EGFR Exon 20 MutationERBB2 Gene MutationRecurrent Lung Non-Small Cell Carcinoma+1 more
M.D. Anderson Cancer Center 93
Testing effectiveness (Phase 2)UnknownNCT05255406
What this trial is testing

Efficacy and Safety of Furmonertinib in EGFR-Mutant, PD-L1+ Patients With Locally Advanced or Metastatic NSCLC (FUTURE)

Who this might be right for
Non-Small-Cell Lung Cancer
Fudan University 62
Testing effectiveness (Phase 2)UnknownNCT04148898
What this trial is testing

Osimertinib With or Without Bevacizumab for EGFR- Mutant Non-small Cell Lung Cancer With Leptomeningeal Metastasis

Who this might be right for
Leptomeningeal MetastasisNon-small Cell Lung CancerEGFR Activating Mutation
Second Affiliated Hospital of Nanchang University 80
Testing effectiveness (Phase 2)Ended earlyNCT04099836
What this trial is testing

Atezolizumab and Bevacizumab in EGFR Mutant NSCLC in Patients With Progressive Disease After Receiving Osimertinib

Who this might be right for
Non Small Cell Lung Cancer
Duke University 7
Testing effectiveness (Phase 2)Study completedNCT04120454
What this trial is testing

Ramucirumab and Pembrolizumab for the Treatment of EGFR Mutant Recurrent or Metastatic Non-small Cell Lung Cancer

Who this might be right for
Metastatic Lung Non-Small Cell CarcinomaRecurrent Lung Non-Small Cell CarcinomaStage IV Lung Cancer AJCC v8+2 more
Ohio State University Comprehensive Cancer Center 6
Next Page